Compare XRX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | ABSI |
|---|---|---|
| Founded | 1906 | 2011 |
| Country | United States | United States |
| Employees | 22900 | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.6M | 357.9M |
| IPO Year | 2019 | 2021 |
| Metric | XRX | ABSI |
|---|---|---|
| Price | $2.78 | $5.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $6.96 |
| AVG Volume (30 Days) | ★ 7.7M | 5.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 23.26 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | $4,534,000.00 |
| Revenue This Year | $8.96 | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $2.24 |
| 52 Week High | $6.80 | $6.24 |
| Indicator | XRX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 78.20 |
| Support Level | $2.33 | $2.52 |
| Resistance Level | $2.89 | N/A |
| Average True Range (ATR) | 0.27 | 0.54 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 77.44 | 88.70 |
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.